Effect of suleparoide on fibrinolysis in the anterior chamber of rabbits

Ophthalmic Research

Volumn 28, Issue 3, 1996, Pages 176-183

  Lepri, Antonio ^a   Benelli, Umberto ^a   Chetoni, Patrizia ^b   Perini, Genoveffa ^b   Fabrizio Saettone, Marco ^b   Nardi, Marco ^a  

^a Institute of Ophthalmology   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Anterior chamber; Fibrin; Heparan sulphate; Rabbit

Indexed keywords

FIBRIN; HEPARIN DERIVATIVE; SULEPAROIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTERIOR EYE CHAMBER; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORNEA THICKNESS; DRUG EFFICACY; EYE SURGERY; FIBRIN CLOT; FIBRIN DEPOSITION; FIBRIN FORMATION; FIBRINOLYSIS; INTRAOCULAR PRESSURE; MALE; MEMBRANE FORMATION; NONHUMAN; PARACENTESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RABBIT; SLIT LAMP;

EID: 0029977038     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000267900     Document Type: Article

References (24)

1. Sebestycn JG: Fibrinoid syndrome: A severe complication of vitrectomy surgery in diabetes, Ann Ophthalmol 1982:14:853-856.
2. Lewis H, Han D, Williams GA: Management of fibrin pupillary-block glaucoma after pars plana vitrectomy with intravitreal gas injection, Am J Ophthalmol 1987:103: 108-109.
3. Chee CKL, Lint ASM: Severe fibrinous membrane formation after cxtracapsular cataract extraction, Implants Ophthalmol 1988:2:140-147.
4. Tripathi RC, Tripathi BJ, Park JK, Quaranta L, Steinsapir K, Lehman E, Ernest JT: Intracameral tissue plasminogen activator for resolution of fibrin clots after glaucoma filtering procedures, Am J Ophthalmol 1991;111:247-248.
5. Flach AJ, Kraft MF, Sanders DR, Tanenbaum: The quantitative effect of 0,5% ketorolac tromctham-inc solution and 0,1% dexametha-sone sodium phosphate solution on postsurgical blood-aqueous barrier, Arch Ophthalmol 1988; 106:480-483.
6. Johnson RN, Balyeat E, Stern WH: Heparin prophylaxis for intra-ocular fibrin, Ophthalmology 1987:94: 597-601.
7. Lindahl U, Pejler G: Heparin-like polysaccharides in intra- and extra-vascular coagulation reactions, Acta MedScand 1987;715:139-144.
8. Snyder RW, Lambrou FH, Williams GA: Intraocular fibrinolysis with recombinant human tissue plasminogen activator, Experimental treatment in a rabbit model, Arch Ophthalmol 1987;105:1277-1280.
9. Johnson RN, Olsen K, Hernandez E: Tissue plasminogen activator treatment of postoperative intraocular fibrin, Ophthalmology 1988:95: 592-596.
10. Williams GA, Lambrou FH, Jaffe GA, Snyder RW, Green GDJ, Devc-nyi RG, Abrams GW: Treatment of postvitrcctomy fibrin formation with intra-ocular tissue plasminogen activator, Arch Ophthalmol 1988: 106:1055-1058.
11. Rowland FN, Donovon MJ, Gillies C, O'Rourke J, Kreutzer DL: Fibrin: Mediator of in vivo and in vitro injury and inflammation, Curr Eye Res 1985:4:537-552.
12. Tsukahara I, Takeuchi S, Ishida M, Nakahara M, Miyazawa Y, Ogawa M, Sagawa A: Effect of intravitreal urokinase in postvitrectomy fibrin formation, Jpn J Clin Ophthalmol 1992;46:465-468.
13. Friedman MW: Streptokinase in ophthalmology, Am J Ophthalmol 1951:34:1692-1696.
14. Snyder RW, Sherman MD, Allinson RW: Intracameral tissue plasminogen activator for treatment of excessive fibrin response after penetrating keratoplasty, Am J Ophthalmol 1990:109:483-484.
15. JafTc GJ, Abrams GW, Williams GA, Han DP: Tissue plasminogen activator for postvitrectomy fibrin formation, Ophthalmology 1990:97: 184-189.
16. Williams DF, Han DP, Abrams GW: Rcblecding in experimental traumatic hyphema treated with intraocular tissue plasminogen activator, Arch Ophthalmol 1990:108: 264-266.
17. Johnson R, Blankenship G: A prospective, randomized clinical trial of heparin therapy for postoperative intra-ocular fibrin, Ophthalmology 1988:95:312-317.
18. Iverson DA, Katsura H, Hartzer MK, Blumenkranz MS: Inhibition of intra-ocular fibrin formation following infusion of low-molecular weight heparin during vitrectomy, Arch Ophthalmol 1991:109:405-409.
19. Gallagher JT, Lyon M, Steward WP: Structure and function of heparan sulphate proteoglycans, Biochem J 1986;236:313-325.
20. Bianchini P, Osima B, Parma B, Nader HB, Dietrich CP: Lack of correlation between in vitro and in vivo antithrombotic activity of heparin fractions and related compounds, Heparan sulphate as an antithrombotic agent in vivo, Thromb Res 1985:40:597-607.
21. Bollu J, Kumar S: Effects of heparin, heparan sulphate and dermatan sulphate on fibrinolysis by tissue plasminogen activator, FASEBJ 1988;2: 277.
22. Casu B, Johnson EA, Mantovani M, Mullov B, Orcstc P, Pcscador R, Pri-no G, Torri G, Zoppetti G: Correlation between structure, fat-clearing and anticoagulant properties of hep-arins and heparan sulphates, Arz-neimitlelforschung Drug Res 1983: 33:135-142.
23. Tripathi RC, Park JK, Tripathi BJ, Millard CB: Tissue plasminogen activator in human aqueous humor and its possible therapeutic significance, Am J Ophthalmol 1988:106: 719-722.
24. Spitznas M, Wcrdermann D, Bokcr T, Fibrinous reaction occurs until 8 days after intra-ocular lens implantation, Arch Ophthalmol 1990:108: 1666.